Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 2

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 2
---
Preferred Stock as described herein under “Description of Series B Preferred Stock — Redemption.”

We elected to be taxed as a REIT for U.S. federal
income tax purposes commencing with our taxable year ended December 31, 2016. To assist us in complying with certain U.S. federal
income tax requirements applicable to REITs, among other purposes, our charter generally limits beneficial and constructive ownership
by any person to no more than 9.8% in value or in number of shares, whichever is more restrictive, of the outstanding shares of any class
or series of our capital stock. In addition, our charter, including the Articles Supplementary establishing the terms of the Series B
Preferred Stock, contains various other restrictions on the ownership and transfer of our Series B Preferred Stock. See “Description
of Series B Preferred Stock—Restrictions on Ownership and Transfer” in this prospectus supplement.

No current market exists for our Series B
Preferred Stock. We intend to apply to list the Series B Preferred Stock on the NYSE under the symbol “GMRE PrB.” If
the listing application is approved, we expect trading of the Series B Preferred Stock to commence within 30 days after initial delivery
of the shares of Series B Preferred Stock. Our common stock is traded on the NYSE under the symbol “GMRE.”

Investing in our Series B Preferred Stock involves risks. See “Risk Factors” beginning on page S-8 of this prospectus supplement and in the reports we file with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, incorporated by reference in this prospectus supplement and the accompanying prospectus, to read about factors you should consider before making an investment in the Series B Preferred Stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                        |     | Per Share |     | Total |
|:---------------------------------------|:----|:----------|:----|:------|
| Public offering price                  |     | $         |     | $     |
| Underwriting discounts and commissions |     | $         |     | $     |
| Proceeds, before expenses, to us       |     | $         |     | $     |

We have granted the underwriters an option to
purchase up to an additional shares of Series B Preferred Stock from
us at the public